Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

Following much opposition from drugmakers, Germany has scrapped its plan to install a program that would have reduced the ...

In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...

IQVIA Digital has developed technology to help pharma marketers identify nurse practitioners (NPs) and physician associates ...

As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled ...

After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has ...

In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought ...

While patients in Novo trials don't need to take any action, the company recommends patients "remain vigilant and report to ...

Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...

The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.

As oncology drug development becomes more biomarker-driven, the industry is rethinking what meaningful early insight looks like and how it can shape better decisions across the life cycle of a program ...

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which ...